EML Awarded Northern Ireland Government Tender For AU$273million Economic Stimulus Solution
29.7.2021 14:11:00 EEST | Business Wire | Press release
EML Payments (ASX: EML) (S&P/ASX 200) is delighted to win a tender to disburse an AU$273million economic stimulus boost to the citizens of Northern Ireland through Mastercard prepaid cards. The new High Street Scheme (HSS) will provide everyone resident in Northern Ireland, aged 18 and over, with a prepaid card worth £100 to spend in local businesses. It follows the innovative, world-first card-based stimulus solution that EML and Mastercard developed for the Government of Jersey in 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005550/en/
Pictured in Carrickfergus, County Antrim: Far left, Lee Britton, CEO Europe at EML, centre with card, Gordon Lyons, Northern Ireland's Minister for the Economy, and second from right, Sarah Cunningham, Vice President and Lead at Mastercard’s Dublin Technology Hub. (Photo: Business Wire)
''This scheme is a key element of my Department’s Economic Recovery Action Plan and will give a very welcome boost to our high streets, which were hard hit by the COVID-19 pandemic,'' commented Gordon Lyons, Northern Ireland's Minister for the Economy.
''Using our payment technology, the Northern Ireland Government can determine how much, where and over what timeframe taxpayers’ funds can be spent, maximising the impact and benefits for the communities and businesses in which they are trying to reach,’’ explained Kelly Devine, Divisional President, UK and Ireland at Mastercard.
''Our award-winning economic stimulus product trusted by governments worldwide will help to boost the Northern Ireland economy by AU$273million,'' stated Lee Britton, CEO Europe at EML.
EML is committed to helping governments worldwide to get money to people who need it most - fast. Most recently, citizens in the United States, the United Kingdom, Jersey, Australia, Spain, Italy and Finland have been assisted with innovative Disbursement-as-a-Service (DaaS) payment solutions across 562 EML initiatives.
About EML Payments
EML provides an innovative payment solutions platform, helping businesses all over the world create awesome customer experiences. Wherever money is in motion, our agile technology can power the payment process, so money can be moved quickly, conveniently and securely. We offer market-leading programme management and highly skilled payments expertise to create customisable feature-rich solutions for businesses, brands and their customers.
Come and explore the many opportunities our platform has to offer by visiting us at: EMLPayments.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005550/en/
Contact information
Sarah Bowles, Group Chief Digital Officer
EML Payments Limited (ASX: EML)
sbowles@emlpayments.com
+61 439 730 968
Marie O’Riordan, Global Director of Public Relations
EML Payments Limited (ASX: EML)
marie.oriordan@emlpayments.com / pr@emlpayments.com
+353 46 94 2010 9 / +44 207 183 5856
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 23:30:00 EET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Multi-Color Corporation Receives Court Approval of First Day Motions4.2.2026 22:30:00 EET | Press release
Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced that it has received approval from the U.S. Bankruptcy Court for the District of New Jersey (the “Court”) for first day relief related to its prepackaged Chapter 11 filed on January 29, 2026. The approved relief affirms that the Company will operate in the normal course, pay all trade vendors and suppliers in full, and maintain a strong liquidity position during the restructuring. As part of this relief, the Court granted MCC immediate access to $125 million of $250 million in debtor-in-possession (“DIP”) new money financing, provided by certain holders of MCC’s secured first lien debt and its equity sponsor, CD&R. This funding will capitalize the business through the initial stages of the prepackaged Chapter 11 process. The Court also granted MCC authority to pay trade vendors and suppliers in full in the ordinary course, maintain wages and benefits without interruption, satisfy
InterSystems Honored with Four 2026 Best in KLAS Awards4.2.2026 19:00:00 EET | Press release
InterSystems, a creative data technology provider powering more than one billion health records globally, today announced it has received four Global 2026 Best in KLAS awards. The company earned a #1 ranking for Acute Care EHR in Asia, Oceania, and France, as well as for Shared Care Records in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204241673/en/ InterSystems earns four Best in KLAS awards for 2026 Best in KLAS is KLAS Research’s annual recognition of top-performing healthcare technology and services solutions, based entirely on feedback from healthcare provider organizations. Awards are given within defined software and services market segments evaluated by KLAS Research using a standardized methodology that reflects customer experience and performance. In addition to U.S. market segments, KLAS also recognizes top-performing solutions through its Global (Non-U.S.) Best in KLAS Awards, which are based on fe
Onego Bio Strengthens Board with Appointment of Dr. Antti Vasara4.2.2026 17:00:00 EET | Press release
Onego Bio, the food ingredient company producing non-animal egg protein through precision fermentation, today announced that Dr. Antti Vasara has joined its board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204881159/en/ Dr. Antti Vasara Dr. Vasara brings more than 25 years of global experience in science, technology, and commercial strategy. Most recently, he served as President and CEO of VTT Technical Research Centre of Finland, where he led one of Europe’s foremost deep tech research organizations. His distinguished career spans senior leadership roles in industry and innovation policy—including impactful work with Nokia and strategic contributions to European research and development initiatives. “Antti is one of the most respected leaders in science and innovation,” said Maija Itkonen, CEO of Onego Bio. “His deep understanding of technology commercialization and ecosystem level strategy will be inva
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom